Model rHlgM22 - Remyelinating Antibody
From Product Pipeline
rHIgM22 is a remyelinating antibody that has been studied for the treatment of multiple sclerosis (MS). MS is a chronic, usually progressive disease in which a person’s own immune system attacks and degrades the function of nerve fibers in the brain and spinal cord by destroying myelin (a process known as demyelination) and eventually the nerve fibers themselves.
-
Most popular related searches
Product Details
Data from two Phase 1 safety and tolerability trials, respectively in patients with MS and acute relapse in MS, showed that a single dose of rHIgM22 was not associated with any safety signals. The studies, which were not powered to show efficacy and exploratory measures, showed no difference between the treatment groups.
Acorda is currently deferring further investment in this program, and is considering next steps, which could include potential partnering or out-licensing.
Customer reviews
No reviews were found for Model rHlgM22 - Remyelinating Antibody. Be the first to review!